Bain Capital Public Equity Management LLC acquired a new stake in Cellectis SA (NASDAQ:CLLS) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 97,710 shares of the biotechnology company’s stock, valued at approximately $2,848,000. Bain Capital Public Equity Management LLC owned 0.27% of Cellectis as of its most recent SEC filing.
Several other large investors have also made changes to their positions in the company. Wells Fargo & Company MN grew its position in Cellectis by 132.1% during the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock valued at $247,000 after acquiring an additional 5,435 shares during the period. KBC Group NV purchased a new stake in Cellectis during the third quarter valued at about $366,000. HBK Investments L P purchased a new stake in Cellectis during the fourth quarter valued at about $498,000. JPMorgan Chase & Co. purchased a new stake in Cellectis during the third quarter valued at about $517,000. Finally, Advisors Asset Management Inc. grew its position in Cellectis by 1,501.1% during the third quarter. Advisors Asset Management Inc. now owns 22,592 shares of the biotechnology company’s stock valued at $643,000 after acquiring an additional 21,181 shares during the period. 20.36% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have issued reports on the company. BidaskClub raised Cellectis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 17th. Zacks Investment Research downgraded Cellectis from a “hold” rating to a “sell” rating in a research report on Wednesday, February 14th. ValuEngine raised Cellectis from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Oppenheimer reissued an “outperform” rating and set a $40.00 price target on shares of Cellectis in a research report on Thursday, December 28th. One research analyst has rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $37.67.
ILLEGAL ACTIVITY WARNING: This news story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/03/13/bain-capital-public-equity-management-llc-takes-position-in-cellectis-sa-clls.html.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.